A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-s
A phase 3 trial of Rilvegostomig, Pembrolizumab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.
Overview
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) is a phase 3 interventional study registered as NCT06692738 by AstraZeneca, with 1160 participants planned, started 2024-11-18 and due to reach its primary completion in 2030-07-01. Interventions recorded: Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung
Shares Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin, Pembrolizumab.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N
Shares Rilvegostomig, AstraZeneca, Carboplatin, Pembrolizumab.
- TrialPhase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥
Shares Rilvegostomig, AstraZeneca, Pembrolizumab, Small-cell lung cancer.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Shares Rilvegostomig, AstraZeneca, Pembrolizumab, Non-small-cell lung cancer.
- TrialA Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Shares Rilvegostomig, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.
- TrialDESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC
Shares Rilvegostomig, Paclitaxel / nab-paclitaxel, AstraZeneca, Carboplatin.
- TrialPembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Pembrolizumab, Small-cell lung cancer.
- TrialA Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
Shares Rilvegostomig, AstraZeneca, Non-small-cell lung cancer.